These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28609172)

  • 21. DNA methylation profiles of genes associated with angiogenesis in the samples of placenta in pregnancies complicated by intrauterine growth restriction.
    Selcen Cebe F; Nur Tola E; Aslan Koşar P; Oral B
    J Matern Fetal Neonatal Med; 2021 Sep; 34(17):2854-2862. PubMed ID: 31581866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
    Gurnadi JI; Mose J; Handono B; Satari MH; Anwar AD; Fauziah PN; Yogi Pramatirta A; Rihibiha DD
    BMC Res Notes; 2015 Oct; 8():534. PubMed ID: 26434493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of placenta growth factor, soluble fms-like tyrosine kinase-1, metal-responsive transcription factor-1, heme oxygenase 1 and hypoxia inducible factor-1α mRNAs in pre-eclampsia placenta and the effect of pre-eclampsia sera on their expression of choriocarcinoma cells.
    Maebayashi Asanuma A; Yamamoto T; Azuma H; Kato E; Yamamoto N; Murase T; Chishima F; Suzuki M
    J Obstet Gynaecol Res; 2014 Oct; 40(10):2095-103. PubMed ID: 25132343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do the physiological aging of the placenta and the changes in angiogenesis marker sFlt-1 and PlGF concentrations predispose patients to late-onset preeclampsia?
    Kwiatkowski S; Dołęgowska B; Kwiatkowska E; Rzepka R; Marczuk N; Loj B; Mikolajek-Bedner W; Torbe A
    J Matern Fetal Neonatal Med; 2019 Jan; 32(1):11-20. PubMed ID: 28816071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of preeclampsia in women with multiple pregnancy after assisted reproduction.
    Romanenko TG; Sulimenko OM
    Wiad Lek; 2020; 73(3):494-497. PubMed ID: 32285820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. sFlt-1/PlGF Ratio at 24 Weeks Gestation in Twin Pregnancies as a Predictor of Preeclampsia or Fetal Growth Restriction.
    Martínez-Varea A; Martínez-Sáez C; Domenech J; Desco-Blay J; Monfort-Pitarch S; Hueso M; Diago-Almela V
    Fetal Diagn Ther; 2022; 49(4):206-214. PubMed ID: 35609518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia.
    Zhao Y; Zheng Y; Liu X; Luo Q; Wu D; Liu X; Zou L
    Mol Hum Reprod; 2018 Mar; 24(3):158-169. PubMed ID: 29325127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia.
    Weel IC; Baergen RN; Romão-Veiga M; Borges VT; Ribeiro VR; Witkin SS; Bannwart-Castro C; Peraçoli JC; De Oliveira L; Peraçoli MT
    PLoS One; 2016; 11(6):e0157584. PubMed ID: 27315098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
    Neuman RI; Baars MD; Saleh L; Broekhuizen M; Nieboer D; Cornette J; Schoenmakers S; Verhoeven M; Koch BCP; Russcher H; van den Berg SAA; van den Meiracker AH; Visser W; Danser AHJ
    Hypertension; 2022 Jun; 79(6):1297-1307. PubMed ID: 35341328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor®.
    Dröge LA; Höller A; Ehrlich L; Verlohren S; Henrich W; Perschel FH
    Pregnancy Hypertens; 2017 Apr; 8():31-36. PubMed ID: 28501276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
    Bdolah Y; Lam C; Rajakumar A; Shivalingappa V; Mutter W; Sachs BP; Lim KH; Bdolah-Abram T; Epstein FH; Karumanchi SA
    Am J Obstet Gynecol; 2008 Apr; 198(4):428.e1-6. PubMed ID: 18191808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternal endothelial damage as a disorder shared by early preeclampsia, late preeclampsia and intrauterine growth restriction.
    Kwiatkowski S; Dołegowska B; Kwiatkowska E; Rzepka R; Marczuk N; Loj B; Torbè A
    J Perinat Med; 2017 Oct; 45(7):793-802. PubMed ID: 27865093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration.
    Herraiz I; Simón E; Gómez-Arriaga PI; Martínez-Moratalla JM; García-Burguillo A; Jiménez EA; Galindo A
    Int J Mol Sci; 2015 Aug; 16(8):19009-26. PubMed ID: 26287164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.
    Alahakoon TI; Zhang W; Trudinger BJ; Lee VW
    J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia.
    Molvarec A; Szarka A; Walentin S; Szucs E; Nagy B; Rigó J
    Hypertens Res; 2010 Sep; 33(9):892-8. PubMed ID: 20535121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies.
    Dröge L; Herraìz I; Zeisler H; Schlembach D; Stepan H; Küssel L; Henrich W; Galindo A; Verlohren S
    Ultrasound Obstet Gynecol; 2015 Mar; 45(3):286-93. PubMed ID: 25491901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke.
    Mehendale R; Hibbard J; Fazleabas A; Leach R
    Am J Obstet Gynecol; 2007 Oct; 197(4):363.e1-5. PubMed ID: 17904960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Assessment of Soluble FMS-Like Tyrosine Kinase-1/Placental Growth Factor Ratio for the Diagnostic and the Prognosis of Preeclampsia in the Second Trimester.
    Chelli D; Hamdi A; Saoudi S; Jenayah AA; Zagre A; Jguerim H; Bedis C; Sfar E
    Clin Lab; 2016 Oct; 62(10):1927-1932. PubMed ID: 28164532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.